<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02114502</url>
  </required_header>
  <id_info>
    <org_study_id>2013-0892</org_study_id>
    <nct_id>NCT02114502</nct_id>
  </id_info>
  <brief_title>Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma</brief_title>
  <official_title>Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if carfilzomib and vorinostat combined&#xD;
      with gemcitabine, busulfan, and melphalan with a stem cell transplant will help to control&#xD;
      multiple myeloma (MM). Researchers also want to learn about the safety and effectiveness of&#xD;
      this combination.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Busulfan Test Dose:&#xD;
&#xD;
      Participant will receive a test dose of busulfan by vein over about 60 minutes. This&#xD;
      low-level test dose of busulfan is to check how the level of busulfan in participant's blood&#xD;
      changes over time. This information will be used to decide the next dose needed to reach the&#xD;
      target blood level that matches participant's body size. Participant will most likely receive&#xD;
      this as an outpatient during the week before they are admitted to the hospital. If it cannot&#xD;
      be given to participant as an outpatient, they will be admitted to the hospital on Day -11&#xD;
      (11 days before participant's stem cells are returned to their body) and the test dose will&#xD;
      be given on Day -10.&#xD;
&#xD;
      About 11 samples of blood (about 1 teaspoon each time) will be drawn for pharmacokinetic (PK)&#xD;
      testing of busulfan. PK testing measures the amount of study drug in the body at different&#xD;
      time points and will help the study doctor decide what participant's dose of busulfan in this&#xD;
      study should be. These blood samples will be drawn at various timepoints before participant&#xD;
      receives busulfan and over about the next 11 hours. The blood samples will be repeated again&#xD;
      on the first day of high-dose busulfan treatment (Day -8). A temporary heparin lock line will&#xD;
      be placed in participant's vein to lower the number of needle sticks needed for these draws.&#xD;
      If it is not possible for the PK tests to be performed for technical or scheduling reasons,&#xD;
      participant will receive the standard fixed dose of busulfan.&#xD;
&#xD;
      If participant receives the busulfan test dose as an outpatient:&#xD;
&#xD;
      On Days -12, -11, and -10, participant will receive palifermin by vein over about 30 seconds&#xD;
      each day to help decrease the risk of side effects in the mouth and throat.&#xD;
&#xD;
      Participant will be admitted to the hospital on Day -9.&#xD;
&#xD;
      If participant receives the busulfan test dose as an inpatient:&#xD;
&#xD;
      On Days -14, -13, and -12, participant will receive palifermin by vein over about 30 seconds&#xD;
      each day to help decrease the risk of side effects in the mouth and throat.&#xD;
&#xD;
      Participant will be admitted to the hospital on Day -11.&#xD;
&#xD;
      Study Drug Administration (for all participants):&#xD;
&#xD;
      With stem cell transplants, the days before participant receives their stem cells are called&#xD;
      minus days. The day participant receives the stem cells is called Day 0. The days after&#xD;
      participant receives their stem cells are called plus days.&#xD;
&#xD;
      Beginning on Day -9, participant will swish the liquids caphosol and glutamine in their mouth&#xD;
      4 times a day, for about 2 minutes each time. Participant will swish these liquids every day&#xD;
      until they leave the hospital. These drugs are used to help decrease the risk of side effects&#xD;
      in the mouth and throat.&#xD;
&#xD;
      On Day -9 through Day -2, participant will receive dexamethasone 2 times a day by vein over&#xD;
      about 10 minutes.&#xD;
&#xD;
      On Day -8 through Day -2, participant will take vorinostat by mouth, with food.&#xD;
&#xD;
      On Day -8, participant will receive gemcitabine by vein over about 4 hours.&#xD;
&#xD;
      On Days -8, -7, -6, and -5, participant will receive busulfan by vein over about 3 hours.&#xD;
&#xD;
      On Days -7 and -6, participant will receive carfilzomib by vein over about 2-10 minutes.&#xD;
&#xD;
      On Day -3, participant will receive gemcitabine by vein over about 4 hours and melphalan by&#xD;
      vein over 30 minutes.&#xD;
&#xD;
      On Day -2, participant will receive carfilzomib by vein over about 2-10 minutes and melphalan&#xD;
      by vein over about 30 minutes.&#xD;
&#xD;
      On Day -1, participant will receive carfilzomib by vein over about 2-10 minutes.&#xD;
&#xD;
      On Day 0, participant will receive their stem cells by vein over about 30-60 minutes.&#xD;
&#xD;
      Participant will receive 3 more doses of palifermin by vein over about 15-30 seconds on Days&#xD;
      0, +1 and +2.&#xD;
&#xD;
      As part of standard care, participant will receive G-CSF (filgrastim) as an injection just&#xD;
      under their skin 1 time a day starting on Day +5 until their blood cell levels return to&#xD;
      normal.&#xD;
&#xD;
      Study Tests:&#xD;
&#xD;
      About 1 month, 100 days, 6 months, 1 year, and then about every 3-6 months for at least 2&#xD;
      years after the transplant:&#xD;
&#xD;
        -  Participant will have a physical exam.&#xD;
&#xD;
        -  Blood (about 4 tablespoons) will be drawn for routine tests, to learn how the transplant&#xD;
           has taken, and to check the status of the disease.&#xD;
&#xD;
      About 100 days after the transplant, participant will have a bone marrow biopsy and&#xD;
      aspiration to check the status of the disease. To collect a bone marrow biopsy and aspirate,&#xD;
      an area of the hip or other site is numbed with anesthetic, and a small amount of bone and&#xD;
      bone marrow is withdrawn through a large needle. This will be repeated once a year or&#xD;
      earlier, if participant's doctor thinks it is needed.&#xD;
&#xD;
      Once a year, participant will have x-rays of all the bones in their body to check the status&#xD;
      of the disease.&#xD;
&#xD;
      The study staff will also stay in contact with participant's local doctor to find out if the&#xD;
      disease comes back and to check how they are doing.&#xD;
&#xD;
      Length of Treatment:&#xD;
&#xD;
      As part of standard care, participant will remain in the hospital for about 3-4 weeks after&#xD;
      the transplant. After participant is released from the hospital, they will continue as an&#xD;
      outpatient in the Houston area to be monitored for infections and transplant-related&#xD;
      complications.&#xD;
&#xD;
      Participant will be taken off study about 2 years after the transplant. Participant may be&#xD;
      taken off study early if the disease gets worse, if intolerable side effects occur, or if&#xD;
      they are unable to follow study directions.&#xD;
&#xD;
      If for any reason participant wants to leave the study early, they must talk to the study&#xD;
      doctor. It may be life-threatening to leave the study after participant has started to&#xD;
      receive the study drugs but before they receive the stem cell transplant because their blood&#xD;
      cell counts will be dangerously low.&#xD;
&#xD;
      This is an investigational study. Carfilzomib and melphalan are FDA approved for the&#xD;
      treatment of MM. Vorinostat is FDA approved for the treatment of cutaneous lymphoma. Busulfan&#xD;
      is FDA approved for the treatment of leukemia. Gemcitabine is FDA approved for the treatment&#xD;
      of lymphoma, breast cancer, and lung cancer. The use of these study drugs in combination is&#xD;
      investigational. The study doctor can explain how the study drugs are designed to work.&#xD;
&#xD;
      Up to 75 participants will take part in this study. All will be enrolled at MD Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>September 2014</start_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Remission (CR) Rate</measure>
    <time_frame>100 days</time_frame>
    <description>Complete remission (CR) rate defined as percentage of number of complete responses in total number of patients treated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rates (RR)</measure>
    <time_frame>100 days</time_frame>
    <description>Response rates (CR; CR/VGPR; RR) reported along with corresponding 95% confidence intervals. Logistic regression used to model the association between response rates and prognostic factors. Overall survival (OS) and progression free survival (PFS) estimated by the Kaplan-Meier method. Comparison of time to event endpoints by subgroups made using the log-rank test. Cox proportional hazards regression employed for univariate and multivariate analysis on time-to-event outcomes.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Myeloma</condition>
  <arm_group>
    <arm_group_label>Carfilzomib/SAHA + Gem/Bu/Mel + Auto Stem Cell Transplant SCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Busulfan test dose of 32 mg/m2 by vein on Day -10 if inpatient, on Day -12 if outpatient, then AUC of 4,000 microMol.min on Days -8 to -5. Palifermin 60 microgram/kg by vein on Days -12 to -10 and Days 0, +1 and +2. SAHA 1,000 mg by mouth on Days -8 to -3. Gemcitabine loading dose of 75 mg/m2 followed by continuous infusion of the remaining dose of 1875 mg/m2 by vein on Days -8 and -3. Carfilzomib 27 mg/m2 by vein on Days -7 and -6, then on Days -2 and -1. SAHA 1,000 mg by mouth on Days -7 to -3. Melphalan 60 mg/m2 by vein on Days -3 and -2. Stem cell transplant on Day 0. Dexamethasone 8 mg by vein twice a day from Day -9 PM to Day -2 PM. Caphosol oral rinses 30 mL four times a day from Day -9 until discharge. Oral glutamine 15 g four times a day, swished, gargled and spit on Day -9 until discharge. Pyridoxine 100 mg by vein or mouth three times a day from Day -1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carfilzomib</intervention_name>
    <description>27 mg/m2 by vein on Days -7 and -6, then on Days -2 and -1</description>
    <arm_group_label>Carfilzomib/SAHA + Gem/Bu/Mel + Auto Stem Cell Transplant SCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAHA</intervention_name>
    <description>1,000 mg by mouth on Days -8 to -3.</description>
    <arm_group_label>Carfilzomib/SAHA + Gem/Bu/Mel + Auto Stem Cell Transplant SCT</arm_group_label>
    <other_name>Vorinostat</other_name>
    <other_name>Suberoylanilide Hydroxamic Acid</other_name>
    <other_name>MSK-390</other_name>
    <other_name>Zolinza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Loading dose of 75 mg/m2 followed by continuous infusion of the remaining dose of 1875 mg/m2 by vein on Days -8 and -3.</description>
    <arm_group_label>Carfilzomib/SAHA + Gem/Bu/Mel + Auto Stem Cell Transplant SCT</arm_group_label>
    <other_name>Gemcitabine Hydrochloride</other_name>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Test dose of 32 mg/m2 by vein on Day -10 if inpatient, on Day -12 if outpatient, then AUC of 4,000 microMol.min on Days -8 to -5.</description>
    <arm_group_label>Carfilzomib/SAHA + Gem/Bu/Mel + Auto Stem Cell Transplant SCT</arm_group_label>
    <other_name>Busulfex</other_name>
    <other_name>Myleran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>60 mg/m2 by vein on Days -3 and -2.</description>
    <arm_group_label>Carfilzomib/SAHA + Gem/Bu/Mel + Auto Stem Cell Transplant SCT</arm_group_label>
    <other_name>Alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem Cell Transplant (SCT)</intervention_name>
    <description>Stem cell transplant on Day 0.</description>
    <arm_group_label>Carfilzomib/SAHA + Gem/Bu/Mel + Auto Stem Cell Transplant SCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palifermin</intervention_name>
    <description>60 microgram/kg by vein on Days -12 to -10 and Days 0, +1 and +2.</description>
    <arm_group_label>Carfilzomib/SAHA + Gem/Bu/Mel + Auto Stem Cell Transplant SCT</arm_group_label>
    <other_name>Kepivance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>8 mg by vein twice a day from Day -9 PM to Day -2 PM.</description>
    <arm_group_label>Carfilzomib/SAHA + Gem/Bu/Mel + Auto Stem Cell Transplant SCT</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caphosol</intervention_name>
    <description>30 mL oral rinse four times a day from Day -9 until discharge.</description>
    <arm_group_label>Carfilzomib/SAHA + Gem/Bu/Mel + Auto Stem Cell Transplant SCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glutamine</intervention_name>
    <description>15 g four times a day, swished, gargled and spit on Day -9 until discharge.</description>
    <arm_group_label>Carfilzomib/SAHA + Gem/Bu/Mel + Auto Stem Cell Transplant SCT</arm_group_label>
    <other_name>Enterex</other_name>
    <other_name>Glutapak-10</other_name>
    <other_name>NutreStore</other_name>
    <other_name>Resource</other_name>
    <other_name>GlutaSolve</other_name>
    <other_name>Sympt-X G.I.</other_name>
    <other_name>Sympt-X</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyridoxine</intervention_name>
    <description>100 mg by vein or mouth three times a day from Day -1.</description>
    <arm_group_label>Carfilzomib/SAHA + Gem/Bu/Mel + Auto Stem Cell Transplant SCT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 to 65 years&#xD;
&#xD;
          2. Refractory or relapsed myeloma, defined as one or more of the following: 1. Patients&#xD;
             with myeloma treated with first-line therapy including lenalidomide, bortezomib or&#xD;
             thalidomide, and one or more of the following: a. Less than partial response to&#xD;
             first-line therapy. b. Relapse after 1st line therapy. 2. High-risk disease, defined&#xD;
             by del(13q) by conventional cytogenetics, or by del(17p), t(4;14), t(14;16), t(14;20)&#xD;
             or 1q+ by FISH. 3. Relapse after a prior autologous stem-cell transplantation (ASCT).&#xD;
             4. Plasma cell leukemia. 5. Plasmablastic lymphoma. 6. Soft tissue plasmacytoma.&#xD;
&#xD;
          3. Adequate renal function, as defined by serum creatinine &lt;/=1.8 mg/dL and/or estimated&#xD;
             serum creatinine clearance &gt;/=50 ml/min.&#xD;
&#xD;
          4. Adequate hepatic function, as defined by serum glutamate oxaloacetate (SGOT) and/or&#xD;
             serum glutamic-pyruvic transaminase (SGPT) &lt;/=3 x upper limit of normal; serum&#xD;
             bilirubin and alkaline phosphatase &lt;/=2 x upper limit of normal, unless proven to be&#xD;
             due to disease involvement.&#xD;
&#xD;
          5. Adequate pulmonary function with FEV1, FVC and DLCO &gt;/=50% of expected corrected for&#xD;
             hemoglobin and/or volume.&#xD;
&#xD;
          6. Adequate cardiac function with left ventricular ejection fraction &gt;/=40%. No&#xD;
             uncontrolled arrhythmias or symptomatic cardiac disease.&#xD;
&#xD;
          7. Zubrod performance status &lt;2.&#xD;
&#xD;
          8. Negative Beta HCG text in a woman with child-bearing potential, defined as not&#xD;
             post-menopausal for 12 months or no previous surgical sterilization.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with grade &gt;/= 3 non-hematologic toxicity from previous therapy that has not&#xD;
             resolved to &lt;/= grade 1.&#xD;
&#xD;
          2. Prior whole brain irradiation.&#xD;
&#xD;
          3. Active hepatitis B, either active carrier (HBsAg +) or viremic (HBV DNA &gt;/=10,000&#xD;
             copies/mL, or &gt;/= 2,000 IU/mL).&#xD;
&#xD;
          4. Evidence of either cirrhosis or stage 3-4 liver fibrosis in patients with chronic&#xD;
             hepatitis C or positive hepatitis C serology.&#xD;
&#xD;
          5. Active infection requiring parenteral antibiotics.&#xD;
&#xD;
          6. HIV infection, unless the patient is receiving effective antiretroviral therapy with&#xD;
             undetectable viral load and normal CD4 counts.&#xD;
&#xD;
          7. Patients having received radiation therapy to head and neck (excluding eyes), and&#xD;
             internal organs of chest, abdomen or pelvis in the month prior to enrollment.&#xD;
&#xD;
          8. Autologous stem-cell transplant in the previous six months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yago Nieto, MD,PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>April 11, 2014</study_first_submitted>
  <study_first_submitted_qc>April 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2014</study_first_posted>
  <last_update_submitted>July 9, 2014</last_update_submitted>
  <last_update_submitted_qc>July 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myeloma</keyword>
  <keyword>Multiple myeloma</keyword>
  <keyword>MM</keyword>
  <keyword>Refractory</keyword>
  <keyword>Relapsed</keyword>
  <keyword>Stem Cell Transplant</keyword>
  <keyword>SCT</keyword>
  <keyword>Carfilzomib</keyword>
  <keyword>SAHA</keyword>
  <keyword>Vorinostat</keyword>
  <keyword>Suberoylanilide Hydroxamic Acid</keyword>
  <keyword>MSK-390</keyword>
  <keyword>Zolinza</keyword>
  <keyword>Gemcitabine</keyword>
  <keyword>Gemcitabine Hydrochloride</keyword>
  <keyword>Gemzar</keyword>
  <keyword>Busulfan</keyword>
  <keyword>Busulfex</keyword>
  <keyword>Myleran</keyword>
  <keyword>Palifermin</keyword>
  <keyword>Kepivance</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Decadron</keyword>
  <keyword>Melphalan</keyword>
  <keyword>Alkeran</keyword>
  <keyword>Caphosol</keyword>
  <keyword>Glutamine</keyword>
  <keyword>Enterex</keyword>
  <keyword>Glutapak-10</keyword>
  <keyword>NutreStore</keyword>
  <keyword>Resource</keyword>
  <keyword>GlutaSolve</keyword>
  <keyword>Sympt-X G.I.</keyword>
  <keyword>Sympt-X</keyword>
  <keyword>Pyridoxine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pyridoxine</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Vorinostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

